Inhibitex Home Page
spacer
spacer
spacer
Clinical Trial Information

Inhibitex currently has two active Phase II clinical development programs being conducted under active Investigational New Drug (IND) applications with FDA. We are studying the safety and efficacy of INX-189 for the treatment of chronic hepatitis C, and we are evaluating FV-100 for the treatment of shingles (Zoster) and shingles-associated pain.

All of the trials conducted for the INX-189 and FV-100 clinical programs will be listed on www.clinicaltrials.gov, including information regarding study design and investigative centers. Additionally, the progress of the overall INX-189 and FV-100 clinical development programs can be followed via periodic press release announcements which can be found on the Investors section on our website.



spacer
©Copyright 2008 Inhibitex, Inc. 9005 Westside Parkway, Alpharetta, Georgia 30009 tel: 678.746.1100 contact | terms of use | privacy policy